Apollomics (fka CBT Pharmaceuticals) incubated by OrbiMed Asia at inception, is an innovative biopharmaceutical company committed to the discovery and development of oncology combination therapies that harness the immune system and target specific molecular pathways to eradicate cancer. The company’s existing pipeline consists of six development-stage assets including three novel, humanized monoclonal antibodies that restore the body’s immune system to recognize and kill cancer cells, and three targeted therapies against uncontrolled growth signaling pathways.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/29/16 | $9,750,000 | Series A |
OrbiMed Asia | undisclosed |
| 01/09/19 | $100,000,000 | Series B |
CMB International Junson Capital K2VC OrbiMed Asia Pan-Lin Asset Management | undisclosed |
